Exelan Pharmaceuticals Inc., Boca Raton, Florida, has been awarded a maximum $8,748,919 modification (P00008) exercising the fourth one-year option period of a one-year base contract (SPE2D2-19-D-0070) with four one-year option periods for finasteride tablets. This is a fixed- price requirements contract. Location of performance is New York, with a May 28, 2024, performance completion date. Using customers are Defense Department, Department of Veterans Affairs, Indian Health Services and Federal Bureau of Prisons. Type of appropriation is fiscal 2023 through 2024 defense working capital funds. The contracting agency is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania.